Anuh Pharma Q1 FY23 earnings call: Revenue & Margins
Q1 FY23 investor presentation: what the company reported on revenue, margins and capex.
Top 10 Pharmaceuticals & Biotechnology companies on management guidance
See the sector's top 10 — free with your mobile number.
Based on Anuh Pharma Ltd's Q1 FY23 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Q1 FY23 Operating Revenue: Rs. 116.38 Cr, down 1% YoY from Rs. 117.27 Cr in Q1 FY22 (Page 14, 13). Q1 FY23 EBITDA: Rs. 12.14 Cr, up 18% YoY (Q1 FY22: Rs. 10.28 Cr).
From Anuh Pharma Ltd's Q1 FY23 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Q1 FY23 Operating Revenue: Rs. 116.38 Cr, down 1% YoY from Rs. 117.27 Cr in Q1 FY22 (Page 14, 13)
- Domestic Sales Contribution: 61% in Q1 FY23 (up from 49% in Q1 FY22) (Page 9)
- Export Sales Contribution: 39% in Q1 FY23 (down from 51% in Q1 FY22) (Page 9)
- Export sales increased by 50% compared to Q1 FY22 (Page 6)
- Outlook:
- Expect upswing in demand from next quarters, driven by anti-malarial, corticosteroids, diabetic, and expectorant segments (Page 6)
2 more points from Anuh Pharma Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Anuh Pharma Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Anuh Pharma Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Anuh Pharma Ltd said on order book & pipeline — free account, 30 seconds.
Anuh Pharma Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹185 Cr, net profit ₹11 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Anuh Pharma's management said in earlier quarters
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Anuh Pharma Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Anuh Pharma Ltd Q1 FY23 results?
Q1 FY23 Operating Revenue: Rs. 116.38 Cr, down 1% YoY from Rs. 117.27 Cr in Q1 FY22 (Page 14, 13). Q1 FY23 EBITDA: Rs. 12.14 Cr, up 18% YoY (Q1 FY22: Rs. 10.28 Cr).
What is Anuh Pharma Ltd share price analysis?
Anuh Pharma Ltd currently shows a neutral. The stock trades at a P/E of 21.2 with a market cap of ₹937 Cr. Investors should review the full earnings analysis for detailed insights.
Is Anuh Pharma Ltd planning capital expenditure?
Enhanced manufacturing capacity at L&L site for corticosteroids increased to 12 MTPA.
Keep Anuh Pharma Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
